Sangamo Therapeutics (SGMO) Scheduled to Post Earnings on Tuesday

Sangamo Therapeutics (NASDAQ:SGMO) is scheduled to be releasing its earnings data after the market closes on Tuesday, August 6th. Analysts expect Sangamo Therapeutics to post earnings of ($0.16) per share for the quarter.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.05). Sangamo Therapeutics had a negative net margin of 1,749.06% and a negative return on equity of 182.55%. The firm had revenue of $0.48 million during the quarter, compared to analysts’ expectations of $8.51 million. During the same period in the previous year, the firm posted $0.12 earnings per share. On average, analysts expect Sangamo Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Sangamo Therapeutics Trading Down 1.2 %

Shares of Sangamo Therapeutics stock traded down $0.01 on Wednesday, hitting $0.69. The stock had a trading volume of 1,837,355 shares, compared to its average volume of 5,647,032. Sangamo Therapeutics has a 52-week low of $0.29 and a 52-week high of $1.48. The stock has a market cap of $143.49 million, a price-to-earnings ratio of -0.38 and a beta of 1.24. The company’s 50 day moving average price is $0.50 and its 200 day moving average price is $0.62.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on SGMO shares. StockNews.com started coverage on Sangamo Therapeutics in a report on Sunday. They issued a “sell” rating for the company. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Sangamo Therapeutics in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $5.67.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.